circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Q4 2019 Cytokinetics, Inc. Earnings Conference Call
    Mar 3, 2020 4:30 PM EST

    Q4 2019 Cytokinetics, Inc. Earnings Conference Call
    Mar 3, 2020 4:30 PM EST
  • Webcast
    X 31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST

    31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Announce Baseline Characteristics from GALACTIC-HF During ACC.20/WCC
SOUTH SAN FRANCISCO, Calif. , March 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart
Toggle Summary Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS).
Toggle Summary Cytokinetics Reports Fourth Quarter 2019 Financial Results
GALACTIC-HF Continuing Following Second Planned Interim Analysis;  Top-line Results for GALACTIC-HF Expected in Q4 2020 Company Provides 2020 Financial Guidance; More Than Two Years of Cash Runway Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics,
Toggle Summary Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
In Vitro Studies Demonstrate Cardiac Troponin Activator Selectively Activates Cardiac Muscle Fibers with Little Effect on Slow Skeletal Muscle or Fast Skeletal Muscle Expect to Complete SAD/MAD Phase 1 Study of AMG 594 in 2H 2020 SOUTH SAN FRANCISCO, Calif.

EVENTS

There are currently no events to display.